Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 2911 AL 2925

Representing Diversity in the Dish: Using Patient-Derived in Vitro Models to Recreate the Heterogeneity of Neurological Disease

Ghaffari LT, Starr A, Nelson AT, Sattler R.

Front Neurosci. 2018 Feb 9;12:56. doi: 10.3389/fnins.2018.00056. eCollection 2018.

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

Waters S, Tedroff J, Ponten H, Klamer D, Sonesson C, Waters N.

J Huntingtons Dis. 2018;7(1):1-16. doi: 10.3233/JHD-170267.

Huntington’s Disease Clinical Trials Corner: February 2018

Rodrigues FB, Wild EJ.

J Huntingtons Dis. 2018;7(1):89-98. doi: 10.3233/JHD-189001.

Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs

Tewari D, Stankiewicz AM, Mocan A, Sah AN, Tzvetkov NT, Huminiecki L, Horbańczuk JO, Atanasov AG.

Front Aging Neurosci. 2018 Feb 12;10:3. doi: 10.3389/fnagi.2018.00003. eCollection 2018.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

Niemann N, Jankovic J.

Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x.

Pathomechanisms of TDP-43 in neurodegeneration

Gao J, Wang L, Huntley ML, Perry G, Wang X.

J Neurochem. 2018 Feb 27:10.1111/jnc.14327. doi: 10.1111/jnc.14327. Online ahead of print.

Animal models of l-dopa-induced dyskinesia in Parkinson's disease

Cenci MA, Crossman AR.

Mov Disord. 2018 Jul;33(6):889-899. doi: 10.1002/mds.27337. Epub 2018 Feb 28.

Determination of Parameters of Oxidative Stress in vitro Models of Neurodegenerative Diseases-A Review

Feitosa CM, da Silva Oliveira GL, do Nascimento Cavalcante A, Morais Chaves SK, Rai M.

Curr Clin Pharmacol. 2018;13(2):100-109. doi: 10.2174/1574884713666180301091612.

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease

Dean M, Sung VW.

Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018.

Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease

Cardinale A, Fusco FR.

CNS Neurosci Ther. 2018 Apr;24(4):319-328. doi: 10.1111/cns.12834. Epub 2018 Mar 3.

Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders

Nierenberg AA, Ghaznavi SA, Sande Mathias I, Ellard KK, Janos JA, Sylvia LG.

Biol Psychiatry. 2018 May 1;83(9):761-769. doi: 10.1016/j.biopsych.2017.12.014. Epub 2018 Jan 10.

Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic

Miniarikova J, Evers MM, Konstantinova P.

Mol Ther. 2018 Apr 4;26(4):947-962. doi: 10.1016/j.ymthe.2018.02.002. Epub 2018 Feb 8.

Pediatric movement disorders

Badheka R, Barad NK, Sankhla CS.

Neurol India. 2018 Mar-Apr;66(Supplement):S59-S67. doi: 10.4103/0028-3886.226447.

Tardive syndromes

Savitt D, Jankovic J.

J Neurol Sci. 2018 Jun 15;389:35-42. doi: 10.1016/j.jns.2018.02.005. Epub 2018 Feb 5.

Antioxidant and Cell-Signaling Functions of Hydrogen Sulfide in the Central Nervous System

Shefa U, Kim MS, Jeong NY, Jung J.

Oxid Med Cell Longev. 2018 Feb 4;2018:1873962. doi: 10.1155/2018/1873962. eCollection 2018.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias